Drug Discovery Pipeline

Domainex programme shows great promise for the treatment of inflammatory diseases, such as Chronic Obstructive Pulmonary Disease (COPD).
Domainex Ltd has developed a number of chemical series with potent and selective activity against two closely related kinases TBK1 and IKK- epsilon.
Domainex and Horizon announce collaboration in support of Domainex's TBK1/IKKe Inhibitor Program.
Domainex has been awarded a £250,000 grant by the Technology Strategy Board to support development of a new drug for treatment of several common cancers.
Domainex works with Sigma-Aldrich to advance the study of epigenetic proteins involved in cancer and stem cell biology using Combinatorial Domain Hunting CDH.